VivoSeq
Hematology

Bone Marrow Transplant

0

Pipeline Programs↗

3

Active Trials↗

0

Companies Involved↗

Bone Marrow Transplant is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

20/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

41

clinical trials

Completed27 · 66%
Terminated8 · 20%
Unknown status3 · 7%
Active, not recruiting2 · 5%
Enrolling by invitation1 · 2%

Clinical Trials

Trial Activity

41 trials

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04872595·59 enrolled
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Enrolling by invitation·—·Phase 1/2·NCT01852370·16 enrolled
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 3·NCT00265837·72 enrolled
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
Completed·MMedical College of Wisconsin·Phase 3·NCT00075816·551 enrolled
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
Completed·National Cancer Institute (NCI)·Phase 3·NCT00001937·800 enrolled
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005797·125 enrolled
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Completed·Children's Oncology Group·Phase 3·NCT00450450·27 enrolled
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT04965597·40 enrolled
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
Completed·EEmory University·Phase 1·NCT01917708·10 enrolled
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134004·210 enrolled
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Completed·MMedical College of Wisconsin·Phase 2·NCT00849147·55 enrolled
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00028730·25 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Completed·National Cancer Institute (NCI)·Phase 1·NCT01254578·17 enrolled
Prevention of RSV Infections in Bone Marrow Transplant Recipients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00001903·120 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)